3児の親さん薬剤師のブログ

とある薬剤師です。感染症治療を考える素材をちょこっと提供。noteもあります https://note.com/twin1980

Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study.

BMJに報告された、グループAレンサ球菌による咽頭扁桃炎患者に対するペニシリンV投与法のRCT。非劣性マージンは10%。

 

www.ncbi.nlm.nih.gov

 

感想 まとめ

 

非劣勢であった研究。

RCTはPK/PDの濃霧を超えて結果が示されるのでスキリする。

 

  • Patients aged 6 years and over with pharyngotonsillitis caused by group A streptococci
  • Penicillin V 800 mg four times daily for five days (total 16 g)
  • Penicillin V 1000 mg three times daily for 10 days (total 30 g)
  • Clinical cure in the per protocol population was 89.6% (n=181/202) in the five day group and 93.3% (n=182/195) in the 10 day group (95% confidence interval -9.7 to 2.2).

 

Abstract


OBJECTIVE:

To determine whether total exposure to penicillin V can be reduced while maintaining adequate clinical efficacy when treating pharyngotonsillitis caused by group A streptococci.

 

DESIGN:
Open label, randomised controlled non-inferiority study.

 

SETTING:
17 primary healthcare centres in Sweden between September 2015 and February 2018.

 

PARTICIPANTS:
Patients aged 6 years and over with pharyngotonsillitis caused by group A streptococci and three or four Centor criteria (fever ≥38.5°C, tender lymph nodes, coatings of the tonsils, and absence of cough).

 

INTERVENTIONS:
Penicillin V 800 mg four times daily for five days (total 16 g) compared with the current recommended dose of 1000 mg three times daily for 10 days (total 30 g).

 

MAIN OUTCOME MEASURES:
Primary outcome was clinical cure five to seven days after the end of antibiotic treatment. The non-inferiority margin was prespecified to 10 percentage points. Secondary outcomes were bacteriological eradication, time to relief of symptoms, frequency of relapses, complications and new tonsillitis, and patterns of adverse events.

 

RESULTS:
Patients (n=433) were randomly allocated to the five day (n=215) or 10 day (n=218) regimen. Clinical cure in the per protocol population was 89.6% (n=181/202) in the five day group and 93.3% (n=182/195) in the 10 day group (95% confidence interval -9.7 to 2.2). Bacteriological eradication was 80.4% (n=156/194) in the five day group and 90.7% (n=165/182) in the 10 day group. Eight and seven patients had relapses, no patients and four patients had complications, and six and 13 patients had new tonsillitis in the five day and 10 day groups, respectively. Time to relief of symptoms was shorter in the five day group. Adverse events were mainly diarrhoea, nausea, and vulvovaginal disorders; the 10 day group had higher incidence and longer duration of adverse events.

 

CONCLUSIONS:
Penicillin V four times daily for five days was non-inferior in clinical outcome to penicillin V three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci. The number of relapses and complications did not differ between the two intervention groups. Five day treatment with penicillin V four times daily might be an alternative to the currently recommended 10 day regimen.

 

TRIAL REGISTRATION:
EudraCT 2015-001752-30; ClinicalTrials.gov NCT02712307.

 

 

J-IDEO (ジェイ・イデオ) Vol.3 No.5

J-IDEO (ジェイ・イデオ) Vol.3 No.5